Medical Neurogenetics collection kit (MCL Supply T657) required.
Each collection kit contains 5 microcentrifuge tubes.
1) CSF should be collected from the first drop into the tubes in the numbered order. Fill each tube to the marked line with the required volumes
Tube 1: 0.5 mL
Tube 2: 1.0 mL
Tube 3: 1.0 mL (contains antioxidants necessary to protect the sample integrity)
Tube 4: 1.0 mL
Tube 5: 1.0 mL
- If sample's not blood contaminated, the tubes should be placed on dry ice at bedside
- If sample's are blood contaminated, the tubes should immediately be centrifuged (prior to freezing) and the clear CSF transferred to new similarly labeled tubes, then frozen
- Store samples at -80 until they can be shipped
2) Complete Medical Neurogenetics, LLC request form. Include test required, sample date and date of birth.
3) Label tubes with patient name and ID number, leaving the tube number viewable.
4) Place samples inside a specimen transport bag and the Medical Neurogenetics, LLC request form inside the pouch of the transport bag.
5) Ship samples frozen on dry ice.
|Specimens other than||CSF in special collection kit (MCL supply T657)|
|Anticoagulants other than||NA|
|Specimen Type||Temperature||Time||Special Container|
CSF Neurotransmitter Metabolites (5HIAA, HVA, 3OMD) (NC04) is useful for diagnosis of certain disorders of neurotransmitter metabolism. This testing may also be used for assessment of Variants of Uncertain Significance (VUS) identified during genetic testing (e.g. Next Generation Sequencing or Capillary Sequencing Testing). CLINICAL Monoamine metabolite testing includes homovanillic acid (HVA), 3-O-methyl-Dopa (3-OMD), and 5-hydroxyindole acetic acid (5-HIAA). This test is useful in diagnosing pediatric neurotransmitter diseases affecting dopamine and serotonin metabolism in the brain. Inborn errors of metabolism and various drugs may lead to severe imbalances and disturbances in these neurotransmitter systems that are reflected by changes in the concentration of monoamines metabolites in CSF. Primary inherited defects involve deficiencies in tyrosine and tryptophan hydroxylase, aromatic amino acid decarboxylase, monoamine oxidase, dopamine beta hydroxylase and the dopamine transwporter. Other defects in the biopterin synthesis pathway may also affect dopamine and serotonin metabolism. These disorders are characterized by a wide range of symptoms that may include developmental delay, mental disability, behavioral disturbances, dystonia, seizures, encephalopathy, athetosis and ptosis.
Age 5HIAA HVA 3-O-MD
(years) (nmol/L) (nmol/L) (nmol/L)
0-0.2 208-1159 337-1299 <300
0.2-0.5 179-711 450-1132 <300
0.5-2.0 129-520 294-1115 <300
2.0-5.0 74-345 233-928 <150
5.0-10 66-338 218-852 <100
10-15 67-189 167-563 <100
Adults 67-140 145-324 <100
Interpretation performed by Keith Hyland, Ph.D.
Note: If test results are inconsistent with the clinical presentation, please call our laboratory to discuss the case and/or submit a second sample for confirmatory testing.
Monday through Friday
|Test Id||Test Order Name||Order LOINC Value|
|FNEU||Neurotransmitter Metabolites||Not Provided|
|Result Id||Test Result Name||
Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.